AbbVie completes acquisition of Celsius Therapeutics, Inc. to advance therapies for inflammatory disease
Acquiring Company
AbbVie Inc.
Acquired Company
Celsius Therapeutics, Inc.
North ChicagoCambridgeManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaHealthcareDescription
AbbVie, a pharmaceutical company focused on discovering innovative medicines, has successfully completed the acquisition of Celsius Therapeutics, Inc. This acquisition aligns with AbbVie's commitment to developing novel therapies for inflammatory disease and advancing the potential of CEL383, an anti-TREM1 antibody for the treatment of IBD.
Quick answer
AbbVie Inc. is acquiring Celsius Therapeutics, Inc., announced June 27, 2024. AbbVie Inc. is based in North Chicago, Illinois, United States.
- Who acquired Celsius Therapeutics, Inc?
- AbbVie Inc. agreed to acquire Celsius Therapeutics, Inc. on June 27, 2024.
- How much did AbbVie Inc. pay for Celsius Therapeutics, Inc?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and Celsius Therapeutics, Inc. based?
- AbbVie Inc. is based in North Chicago, Illinois, United States. Celsius Therapeutics, Inc. is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Edwards Lifesciences Completes Acquisitions of JenaValve Technology and Endotronix (July 24, 2024)
- AbbVie completes acquisition of Cerevel Therapeutics to strengthen neuroscience portfolio (August 1, 2024)
- Ligand Pharmaceuticals to acquire APEIRON Biologics AG to enhance royalty portfolio (July 8, 2024)
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical (August 9, 2024)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Celsius Therapeutics, Inc.?
Celsius Therapeutics, Inc. was acquired by AbbVie Inc., based in North Chicago. The deal was reported on June 27, 2024. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Celsius Therapeutics, Inc.?
AbbVie Inc.'s acquisition of Celsius Therapeutics, Inc. was reported on June 27, 2024. AbbVie, a pharmaceutical company focused on discovering innovative medicines, has successfully completed the acquisition of Celsius Therapeutics, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Celsius Therapeutics, Inc. do?
Celsius Therapeutics is a clinical-stage biotechnology company focused on developing novel medicines in inflammatory disease. Its lead therapeutic candidate is an anti-TREM1 antibody for the treatment of IBD. It is privately held, operating in Healthcare, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.